Oculis (NASDAQ:OCS) Stock Price Up 3.7% - Here's Why

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) traded up 3.7% during mid-day trading on Monday . The stock traded as high as $18.30 and last traded at $17.62. 3,889 shares traded hands during trading, a decline of 91% from the average session volume of 43,658 shares. The stock had previously closed at $17.00.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OCS. HC Wainwright lifted their price target on shares of Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, April 17th. Chardan Capital reissued a "buy" rating and issued a $28.00 price target on shares of Oculis in a research note on Thursday, April 17th. Finally, Robert W. Baird lifted their price objective on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th.

Oculis Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The stock has a fifty day simple moving average of $18.45 and a two-hundred day simple moving average of $18.17. The firm has a market capitalization of $780.89 million, a P/E ratio of -9.27 and a beta of 0.19.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, research analysts predict that Oculis Holding AG will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after acquiring an additional 1,800 shares during the period. Bellevue Group AG acquired a new stake in Oculis in the 4th quarter valued at $170,000. Bank of America Corp DE grew its position in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares during the period. XTX Topco Ltd bought a new stake in Oculis during the 4th quarter valued at $225,000. Finally, Citadel Advisors LLC acquired a new position in Oculis during the fourth quarter worth $389,000. Institutional investors own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.